Dr. Tomaselli received his PhD in neuroscience from the University of California, San Francisco (UCSF) in 1988 and did postdoctoral research in the Howard Hughes Medical Institute (HHMI) at UCSF.

He joined Amylin Pharmaceuticals in April 2008. From 2005 to 2007, he was the founding Chief Technology Officer of Ikaria and a co-inventor of IK-1001, a potentially first-in-class, injectable small molecule currently in Phase 2 clinical trials for the treatment of acute myocardial infarction.

From 2003-2005, Dr. Tomaselli was founding Executive Vice President, Operations and Chief Scientific Officer of Ascenta Therapeutics, where he played a role in developing AT-101, a potentially first-in-class, oral small molecule currently in multiple Phase 2 clinical trials in hematologic and solid cancers.

From 1993-2002, he was Co-Founder and Vice President of Science and Technology at Idun Pharmaceuticals, now a wholly owned subsidiary of Pfizer, where he was responsible for pre-clinical drug discovery focused on apoptosis, or programmed cell death, across multiple therapeutic areas, including cancer, CNS, cardiovascular disease and hepatic disease, including the pre-clinical development of IDN-6556, a potentially first-in-class, oral small molecule that is currently in Phase 3 clinical trials for the treatment of viral hepatitis C.

From 1989-1993, he was Senior Scientist at Athena Neurosciences (now Elan Pharmaceuticals) where he worked on small molecule therapeutics targeting Alzheimer’s Disease and other neurodegenerative diseases.

He is a co-author on over 60 peer reviewed scientific papers and is a co-inventor on 18 issued U.S. patents.